Edition:
India

Anthera Pharmaceuticals Inc (ANTH.OQ)

ANTH.OQ on NASDAQ Stock Exchange Global Market

2.21USD
17 Nov 2017
Change (% chg)

$-0.03 (-1.34%)
Prev Close
$2.24
Open
$2.18
Day's High
$2.33
Day's Low
$2.10
Volume
94,978
Avg. Vol
60,956
52-wk High
$20.16
52-wk Low
$1.21

Select another date:

Tue, Nov 14 2017

BRIEF-Anthera Pharmaceuticals files for resale of up to 28.6 million shares of co's common stock

* Anthera Pharmaceuticals Inc files for resale of up to 28.6 million shares of co's common stock by the selling stockholders‍​ Source text: (http://bit.ly/2mmbjHr) Further company coverage:

BRIEF-ANTHERA PHARMA REPORTS Q3 LOSS PER SHARE $0.58

* ANTHERA PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS 2017 THIRD QUARTER FINANCIAL RESULTS

BRIEF-Armistice Capital reports 5.6 percent passive stake in Anthera Pharma

* Armistice Capital, Llc reports 5.6 percent passive stake in Anthera Pharmaceuticals Inc as on October 24, 2017 - SEC filing‍​ Source text: (http://bit.ly/2A4C2Kr) Further company coverage:

BRIEF-Anthera Pharmaceuticals announces pricing of $15 mln private placement offering

* Anthera Pharmaceuticals announces pricing of $15 million private placement offering

BRIEF-Anthera Pharma surpasses 50 pct milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosis

* Anthera Pharmaceuticals surpasses 50% milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosis

BRIEF-Anthera announces top line final data from extension period of phase 2 bright-SC study of blisibimod in patients with iGa nephropathy

* Anthera announces top line final data from the extension period of the phase 2 bright-sc study of blisibimod in patients with IgA nephropathy

BRIEF-Anthera Pharmaceuticals announces result phase 3 clinical study of Sollpura will be included in the European cystic fibrosis clinical trial network

* Anthera Pharmaceuticals announces result phase 3 clinical study of Sollpura will be included in the European cystic fibrosis clinical trial network

BRIEF-FDA grants orphan status to Anthera's kidney disease drug

* Anthera announces FDA orphan drug designation for blisibimod for the treatment of iga nephropathy

BRIEF-Anthera Pharmaceuticals reports Q2 earnings per share $0.03

* Anthera Pharmaceuticals provides business update and reports 2017 second quarter financial results

BRIEF-Anthera Pharmaceuticals announces results of Phase 3 clinical study of Sollpura

* Anthera Pharmaceuticals announces result Phase 3 clinical study of Sollpura will be included in the cystic fibrosis foundation therapeutics development network

Select another date: